Traditional vs Targeted Biopsy

Targeted biopsies for prostate cancer could increase detection of high risk disease and help to prevent over-diagnosis

Multiparametric magnetic resonance imaging (MP-MRI) could transform prostate cancer (PrCa) diagnosis by making tissue biopsies more targeted. But how does it measure up to traditional, well-established methods of obtaining a tissue sample? US National Institutes of Health (NIH) researchers decided to find out…

Currently, the “gold standard” diagnostic procedure for suspected PrCa is an ultrasound-guided, extended-sextant biopsy, which samples different areas of the prostate at random. In contrast, targeted biopsy – which uses MR/ultrasound fusion with MP-MRI images that are superimposed onto the ultrasound in real-time – allows abnormal or unusual areas of the prostate to be identified and selected for sampling. Previous studies have focused on using targeted methods alongside traditional biopsy, but the NIH scientists designed their study to directly compare the two platforms.

A prospective cohort study of 1,003 men showed that targeted biopsy provided increased detection of high-risk PrCa, diagnosing 30 percent more high-risk cancer than standard biopsy. It also diagnosed 17 percent less low-risk cancer, which could prevent diagnosis and overtreatment of patients with latent PrCa. The accuracy of targeted biopsy was 73 percent, compared with 59 percent for standard biopsy, and 69 percent for combination standard and targeted biopsy (1). Although this was only a preliminary study that did not take certain factors into account (e.g. disease recurrence, PrCa-specific mortality), the NIH team are hopeful that MR/ultrasound fusion could significantly alter the risk estimate given to men at diagnosis, which has many obvious clinical benefits.

Newsletters

Receive the latest analytical scientist news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe

References

1. MM Siddiqui et al., “Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer”, JAMA, 313, 390–397 (2015). PMID: 25626035.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan